Sarcoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• ERK 0
• JNK 0
• VEGF 3
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• EGFR 1
• JAK 1
• PARP 4
• YAP 0
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• GPX4 0
• HIF-1 0
• PTEN 0
• EZH2 0
• PPAR 0
• METTL3 1
• NF1 5
• AMPK 0
• GPC3 5
• PDGFR 3
• ABL1 0
• CD47 0
• COX-2 0
• ROS1 2
• AXL 0
• CDKN2A 0
• CXCR4 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• FLT3 0
• FTO 0
• HDAC 0

8 of 8+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• FDA · U01

  Disulfiram/Copper as a Dual Senolytic Strategy Targeting Tumor and Immune Cell Senescence in Chordoma

  Massachusetts General Hospital· Boston, United States· US$1,000,000 awarded in fiscal year 2026· until Aug 2028

• NIH NIA · R01

  Synapse repair in Alzheimer's disease and related dementias

  Buck Institute for Research on Aging· Novato, United States· US$785,081 awarded in fiscal year 2026· until Jul 2031

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, United States· US$350,188 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R21

  Failure to resolve an adaptive stress state contributes to Duchenne Muscular Dystrophy Severity

  University of Southern California· Los Angeles, United States· US$211,650 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma

  Biologica Llc· Charlotte, United States· US$385,056 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €2,302,626· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Self-Assembling, Self-Monitoring, Multi-Stimuli-Responsive Implants for the Minimally Invasive Treatment of Critical-Size Defects (Morphogenesis)

  Fundacion Imdea Materiales· Getafe, Spain· EU contribution €194,075· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres (RBPandALT)

  The Francis Crick Institute Limited· London, United Kingdom· EU contribution €260,348· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting single-cell ploidy from digital pathology images in pan-sarcoma (SImPloidy)

  University College London· London, United Kingdom· EU contribution €276,188· until May 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-IA

  Sustainable 4D hydrogels functionalised with plant-based nanoparticles for bone regeneration in cancer patients (GreenNanoBone)

  The University of Liverpool· Liverpool, United Kingdom· EU contribution €8,649,982· until May 2029· 12 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 473 running projects, newest first. Listed amounts together: US$249.7m + €53.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 41
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 11
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 186
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 153
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 198
• Machine Learning 29
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Ewing Sarcoma PDX Models.

  Methods Mol Biol, Jan 2027

• Using Zebrafish Larvae as a Xenotransplantation Model to Study Ewing Sarcoma.

  Methods Mol Biol, Jan 2027

• Chorioallantoic Membrane Assay to Assess Primary and Metastatic Tumor Growth in Ewing Sarcoma.

  Methods Mol Biol, Jan 2027

• Orthotopic Implants in Mice.

  Methods Mol Biol, Jan 2027

• Tumor Growth Analysis of Ewing Sarcoma Cell Lines Using Subcutaneous Xenografts in Mice.

  Methods Mol Biol, Jan 2027

• PRMT1 blockade reverts resistance to KRAS (G12C) inhibition through modulating ferroptosis signalling.

  Int J Oncol, Nov 2026

• AXL-directed antibody-drug conjugate therapy in soft-tissue sarcoma.

  J Hematol Oncol, Oct 2026

• FTO Promotes Osteosarcoma Progression via YAP and Reduces Cisplatin Sensitivity.

  Front Biosci (Landmark Ed), Oct 2026

• NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition.

  Mol Cancer Ther, Oct 2026

• Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.

  J Immunother Cancer, Sept 2026

  Marcela V Maus

See which targets of this disease your abstract mentions, and go to the people working on them.